ARS Pharmaceuticals (SPRY) Other Non Operating Income (2022 - 2026)

ARS Pharmaceuticals has reported Other Non Operating Income for 5 years, with the latest figure at $2.0 million in Q1 2026.

• Quarterly Other Non Operating Income fell 39.2% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (down 110.83% YoY) and the FY2025 annual result came in at $1000.0, down 99.99% from the prior year.
• Other Non Operating Income improved to $2.0 million in Q1 2026 per SPRY's latest filing, from -$8.0 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $3.8 million in Q1 2023 and troughed at -$8.9 million in Q4 2023.
• A 5-year average of $911235.3 and a median of $2.6 million in 2024 frame the typical range for Other Non Operating Income.
• The widest YoY moves for Other Non Operating Income: up 6521.28% in 2023, down 872.79% in 2023.
• Over 5 years, Other Non Operating Income stood at $1.2 million in 2022, then tumbled by 872.79% to -$8.9 million in 2023, then surged by 133.92% to $3.0 million in 2024, then tumbled by 364.73% to -$8.0 million in 2025, then surged by 124.58% to $2.0 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $2.0 million, -$8.0 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.